Trial · NCT01260688
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 12-week Progression-free Survival as Per the Prostate Cancer Clinical Trials Working Group (PCWG2) | Arm I - Cediranib Plus Dasatinib | 2 | participants | ||
| 12-week Progression-free Survival as Per the Prostate Cancer Clinical Trials Working Group (PCWG2) | Arm II - Cediranib Alone | 8 | participants | ||
| Number of Participants With Toxicities | Arm I - Cediranib Plus Dasatinib | 11 | participants | ||
| Number of Participants With Toxicities | Arm II - Cediranib Alone | 11 | participants | ||
| Qualtiy of Life Assessment Number of Participants With a Score ≥2 on the Present Pain Intensity (PPI) Scale | Arm I - Cediranib Plus Dasatinib | 4 | Participants | ||
| Qualtiy of Life Assessment Number of Participants With a Score ≥2 on the Present Pain Intensity (PPI) Scale | Arm II - Cediranib Alone | 8 | Participants | ||
| Number Who Experienced Study Medication Dose Intensity | Arm I - Cediranib Plus Dasatinib | 6 | participant | ||
| Number Who Experienced Study Medication Dose Intensity | Arm II - Cediranib Alone | 9 | participant | ||
| Treatment Discontinuation | Arm I - Cediranib Plus Dasatinib | 7 | Participants | ||
| Treatment Discontinuation | Arm II - Cediranib Alone | 6 | Participants | ||
| Treatment Discontinuation Due to Adverse Events (AEs) | Arm I - Cediranib Plus Dasatinib | 2 | participants | ||
| Treatment Discontinuation Due to Adverse Events (AEs) | Arm II - Cediranib Alone | 1 | participants | ||
| Non-AE Related Treatment Discontinuation | Arm I - Cediranib Plus Dasatinib | Progressive Disease | 4 | participants | |
| Non-AE Related Treatment Discontinuation | Arm II - Cediranib Alone | Progressive Disease | 4 | participants | |
| Non-AE Related Treatment Discontinuation | Arm I - Cediranib Plus Dasatinib | Death | 0 | participants | |
| Non-AE Related Treatment Discontinuation | Arm II - Cediranib Alone | Death | 2 | participants | |
| Non-AE Related Treatment Discontinuation | Arm I - Cediranib Plus Dasatinib | Other | 5 | participants | |
| Non-AE Related Treatment Discontinuation | Arm II - Cediranib Alone | Other | 4 | participants | |
| Overall Response Rate | Arm I - Cediranib Plus Dasatinib | 2.6 | 95% Confidence Interval 1.4 to NA | months | |
| Overall Response Rate | Arm II - Cediranib Alone | 6.4 | 95% Confidence Interval 1.9 to NA | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01260688/results